Table 1.
Comparison of results of telepsychiatric assessments and face-to-face interviews
| Sample | Accuracy Ratio Statistics | Risk Difference Statistics | ||||||||||
Primary attributes and accuracy
|
A | I | Size | AR | LCI | UCI | p | RD | LCI | UCI | p | |
| 01 | DSM-IV Axis 1 | 49 | 5 | 54 | 0.91 | 0.83 | 0.99 | 0.025 | -0.09 | -0.17 | -0.02 | 0.019 |
| 02 | DSM-IV Axis 2 | 34 | 3 | 37 | 0.92 | 0.84 | 1.01 | 0.083 | -0.08 | -0.17 | 0.01 | 0.071 |
| 03 | DSM-IV Axis 3 | 36 | 2 | 38 | 0.95 | 0.88 | 1.02 | 0.157 | -0.05 | -0.12 | 0.02 | 0.146 |
| 04 | DSM-IV Axis 4 Q1 | 31 | 6 | 37 | 0.84 | 0.73 | 0.97 | 0.014 | -0.16 | -0.28 | -0.04 | 0.007 |
| 05 | DSM-IV Axis 4 Q2 | 31 | 6 | 37 | 0.84 | 0.73 | 0.97 | 0.014 | -0.16 | -0.28 | -0.04 | 0.007 |
| 06 | DSM-IV Axis 4 Q3 | 37 | 0 | 37 | 1.00 | 1.00 | 1.00 | NA | 0.00 | 0.00 | 0.00 | NA |
| 07 | DSM-IV Axis 4 Q4 | 36 | 1 | 37 | 0.97 | 0.92 | 1.03 | 0.317 | -0.03 | -0.08 | 0.03 | 0.311 |
| 08 | DSM-IV Axis 4 Q5 | 37 | 0 | 37 | 1.00 | 1.00 | 1.00 | NA | 0.00 | 0.00 | 0.00 | NA |
| 09 | DSM-IV Axis 4 Q6 | 32 | 5 | 37 | 0.86 | 0.76 | 0.98 | 0.025 | -0.14 | -0.25 | -0.02 | 0.016 |
| 10 | DSM-IV Axis 4 Q7 | 37 | 0 | 37 | 1.00 | 1.00 | 1.00 | NA | 0.00 | 0.00 | 0.00 | NA |
| 11 | DSM-IV Axis 4 Q8 | 34 | 3 | 37 | 0.92 | 0.84 | 1.01 | 0.083 | -0.08 | -0.17 | 0.01 | 0.071 |
| 12 | DSM-IV Axis 4 Q9 | 1 | 36 | 37 | 0.03 | 0.00 | 0.19 | 0.000 | -0.97 | -1.03 | -0.92 | 0.000 |
| 13 | DSM-IV Axis 5 | 26 | 11 | 37 | 0.70 | 0.57 | 0.87 | 0.001 | -0.30 | -0.44 | -0.15 | 0.000 |
| 14 | Risk to Self Q1 | 27 | 10 | 37 | 0.73 | 0.60 | 0.89 | 0.002 | -0.27 | -0.41 | -0.13 | 0.000 |
| 15 | Risk to Self Q2 | 29 | 8 | 37 | 0.78 | 0.66 | 0.93 | 0.005 | -0.22 | -0.35 | -0.08 | 0.001 |
| 16 | Risk to Self Q3 | 28 | 9 | 37 | 0.76 | 0.63 | 0.91 | 0.003 | -0.24 | -0.38 | -0.10 | 0.001 |
| 17 | Risk to Self Q4 | 28 | 9 | 37 | 0.76 | 0.63 | 0.91 | 0.003 | -0.24 | -0.38 | -0.10 | 0.001 |
| 18 | Risk to Others Q1 | 28 | 9 | 37 | 0.76 | 0.63 | 0.91 | 0.003 | -0.24 | -0.38 | -0.10 | 0.001 |
| 19 | Risk to Others Q2 | 35 | 2 | 37 | 0.95 | 0.88 | 1.02 | 0.157 | -0.05 | -0.13 | 0.02 | 0.146 |
| 20 | Risk to Others Q3 | 33 | 4 | 37 | 0.89 | 0.80 | 1.00 | 0.046 | -0.11 | -0.21 | -0.01 | 0.034 |
| 21 | Risk to Others Q4 | 32 | 5 | 37 | 0.86 | 0.76 | 0.98 | 0.025 | -0.14 | -0.25 | -0.02 | 0.016 |
| 22 | Risk to Others Q5 | 33 | 4 | 37 | 0.89 | 0.80 | 1.00 | 0.046 | -0.11 | -0.21 | -0.01 | 0.034 |
| 23 | Risk to Others Q6 | 29 | 8 | 37 | 0.78 | 0.66 | 0.93 | 0.005 | -0.22 | -0.35 | -0.08 | 0.001 |
| 24 | Admit-Discharge-Follow-up | 34 | 3 | 37 | 0.92 | 0.84 | 1.01 | 0.083 | -0.08 | -0.17 | 0.01 | 0.071 |
| 25 | Investigations | 25 | 12 | 37 | 0.68 | 0.54 | 0.84 | 0.001 | -0.32 | -0.48 | -0.17 | 0.000 |
| 26 | Psychological Input | 26 | 11 | 37 | 0.70 | 0.57 | 0.87 | 0.001 | -0.30 | -0.44 | -0.15 | 0.000 |
| 27 | Community Support | 29 | 8 | 37 | 0.78 | 0.66 | 0.93 | 0.005 | -0.22 | -0.35 | -0.08 | 0.001 |
| 28 | Drug Type
|
64 | 11 | 75 | 0.85 | 0.78 | 0.94 | 0.001 | -0.15 | -0.23 | -0.07 | 0.000 |
| 29 | Drug Action
|
58 | 17 | 75 | 0.77 | 0.68 | 0.87 | 0.000 | -0.23 | -0.32 | -0.13 | 0.000 |
| 30 | Drug Indication
|
49 | 26 | 75 | 0.65 | 0.55 | 0.77 | 0.000 | -0.35 | -0.45 | -0.24 | 0.000 |
| Main Attributes | ||||||||||||
| 31 | DSM-IV Axis 1 (1)
|
49 | 5 | 54 | 0.91 | 0.83 | 0.99 | 0.025 | -0.09 | -0.17 | -0.02 | 0.019 |
| 32 | DSM-IV Axis 2 (2) | 34 | 3 | 37 | 0.92 | 0.84 | 1.01 | 0.083 | -0.08 | -0.17 | 0.01 | 0.071 |
| 33 | DSM-IV Axis 3 (3) | 36 | 2 | 38 | 0.95 | 0.88 | 1.02 | 0.157 | -0.05 | -0.12 | 0.02 | 0.146 |
| 34 | DSM-IV Axis 4 (4:12) | 276 | 57 | 333 | 0.83 | 0.79 | 0.87 | 0.000 | -0.17 | -0.21 | -0.13 | 0.000 |
| 35 | DSM-IV Axis 5 (13) | 26 | 11 | 37 | 0.70 | 0.57 | 0.87 | 0.001 | -0.30 | -0.44 | -0.15 | 0.000 |
| 36 | Risk to Self (14:17) | 112 | 36 | 148 | 0.76 | 0.69 | 0.83 | 0.000 | -0.24 | -0.31 | -0.17 | 0.000 |
| 37 | Risk to Others (18:23) | 190 | 32 | 222 | 0.86 | 0.81 | 0.90 | 0.000 | -0.14 | -0.19 | -0.10 | 0.000 |
| 38 | Admit-Discharge-Follow-up (24) | 34 | 3 | 37 | 0.92 | 0.84 | 1.01 | 0.083 | -0.08 | -0.17 | 0.01 | 0.071 |
| 39 | Investigations (25) | 25 | 12 | 37 | 0.68 | 0.54 | 0.84 | 0.001 | -0.32 | -0.48 | -0.17 | 0.000 |
| 40 | Psychological Input (26) | 26 | 11 | 37 | 0.70 | 0.57 | 0.87 | 0.001 | -0.30 | -0.44 | -0.15 | 0.000 |
| 41 | Community Support (27) | 29 | 8 | 37 | 0.78 | 0.66 | 0.93 | 0.005 | -0.22 | -0.35 | -0.08 | 0.001 |
| 42 | Drug Type (28) | 64 | 11 | 75 | 0.85 | 0.78 | 0.94 | 0.001 | -0.15 | -0.23 | -0.07 | 0.000 |
| 43 | Drug Action (29) | 58 | 17 | 75 | 0.77 | 0.68 | 0.87 | 0.000 | -0.23 | -0.32 | -0.13 | 0.000 |
| 44 | Drug Indication (30) | 49 | 26 | 75 | 0.65 | 0.55 | 0.77 | 0.000 | -0.35 | -0.45 | -0.24 | 0.000 |
| Major Attributes | ||||||||||||
| 45 | DSM Diagnosis (1:13) | 421 | 78 | 499 | 0.84 | 0.81 | 0.88 | 0.000 | -0.16 | -0.19 | -0.12 | 0.000 |
| 46 | Risks (14:23) | 302 | 68 | 370 | 0.82 | 0.78 | 0.86 | 0.000 | -0.18 | -0.22 | -0.14 | 0.000 |
| 47 | Non-Drug Intervention (24:27) | 114 | 34 | 148 | 0.77 | 0.71 | 0.84 | 0.000 | -0.23 | -0.30 | -0.16 | 0.000 |
| 48 | Drug Intervention (28:30) | 171 | 54 | 225 | 0.76 | 0.71 | 0.82 | 0.000 | -0.24 | -0.30 | -0.18 | 0.000 |
| Overall | ||||||||||||
| 49 | Overall Result (1:30) | 1008 | 234 | 1242 | 0.81 | 0.79 | 0.83 | 0.000 | -0.19 | -0.21 | -0.17 | 0.000 |
A: Accurate outcome, I: Inaccurate Outcome, AR: Accuracy Ratio (Risk Ratio), LCI: Lower 95% Confidence Interval, UCI: Upper 95% Confidence Interval, RD: Risk Difference when the sample statistics compared with Accuracy (Risk) of 1 for the face-to-face interview. All approximated p values are more than zero.
Numbers in brackets represent index number of primary attributes serialised in the previous rows.
Drug Types- Atypical Antipsychotic, Mood Stabilizer, Tricyclic Antidepressant, Newer Antidepressant, Other Antidepressant, Benzodiazepine Group, Non-Benzodiazepine Anxolytic, Anti-Parkinsonian, and 'No Medication'.
Drug related actions were grouped into 'New Prescription', 'Continuation of previously prescribed medication with no change', and 'Adjustment of previously prescribed medication'.
Drug Indications were categorised for Positive Psychotic Symptoms, Manic symptoms, Bipolar Disorder, Depression, Anxiety and Associated Symptoms, Drugs for Side Effects (e.g. Anti-parkinsonian), Hypnotics, and Use of Drugs' sedative effect for anxiety control and sleep.